nccn guidelines breast cancer genetic testing

Release time ：Dec-20,2024

The NCCN Breast Cancer Genetic Testing Guidelines emphasize the importance of genetic counseling and testing for patients with a family history of breast cancer or other risk factors. These assessments can identify individuals with BRCA1/2 gene mutations or other genetic alterations linked to an elevated risk of breast cancer.

Prior to genetic testing, it is crucial for patients to undergo genetic counseling to comprehend the objectives, procedures, potential risks, and benefits of the test, as well as how the results may affect their personal health and that of their relatives. The testing process typically involves taking blood or saliva samples, which are then analyzed in a laboratory. Results can range from definitive (such as identifying BRCA1/2 mutations), to indeterminate (such as finding variants of uncertain significance), to negative (no known genetic alterations detected). Patients identified with BRCA1/2 mutations may be advised by physicians to undergo more frequent breast cancer screenings, consider prophylactic surgeries, or adopt other risk mitigation strategies.

For those contemplating genetic testing for breast cancer, it is advisable to consult with a genetic counselor or physician first to assess the suitability of the test and understand its potential implications. It is essential to keep in mind that genetic testing does not predict the development of breast cancer; it only provides insights into the level of risk. Thus, a negative test result does not ensure immunity from developing breast cancer in the future.